George Y Wang

Array ( [id] => 17399639 [patent_doc_number] => 20220041729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS [patent_app_type] => utility [patent_app_number] => 17/502602 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17502602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399641 [patent_doc_number] => 20220041731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS [patent_app_type] => utility [patent_app_number] => 17/502922 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17502922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369921 [patent_doc_number] => 20220024973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format [patent_app_type] => utility [patent_app_number] => 17/496263 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414095 [patent_doc_number] => 20220048999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/494545 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882768 [patent_doc_number] => 20220298245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/490606 [patent_app_country] => US [patent_app_date] => 2021-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17490606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792086 [patent_doc_number] => 20220251177 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => METHODS AND COMPOSITIONS RELATING TO ANTI-NUCLEOLIN RECOMBINANT IMMUNOAGENTS [patent_app_type] => utility [patent_app_number] => 17/483101 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24058 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17483101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312930 [patent_doc_number] => 20210401978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => Checkpoint Inhibitor and Vaccine Combinations and Use of Same for Immunotherapy [patent_app_type] => utility [patent_app_number] => 17/474389 [patent_app_country] => US [patent_app_date] => 2021-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17474389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545320 [patent_doc_number] => 11718660 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Recombinant polyclonal proteins targeting Zika and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/469493 [patent_app_country] => US [patent_app_date] => 2021-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 117 [patent_figures_cnt] => 122 [patent_no_of_words] => 51055 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 276 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17469493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460324 [patent_doc_number] => 20220073629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses [patent_app_type] => utility [patent_app_number] => 17/407651 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17407651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398070 [patent_doc_number] => 20220040160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/402751 [patent_app_country] => US [patent_app_date] => 2021-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10434 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17402751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299487 [patent_doc_number] => 20210395326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => THERAPEUTIC COMPOUNDS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/396127 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17396127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411787 [patent_doc_number] => 12077594 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => IL2RG binding molecules and methods of use [patent_app_type] => utility [patent_app_number] => 18/006525 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32046 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18091384 [patent_doc_number] => 20220409725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => MULTISPECIFIC ANTIGEN-BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 17/395400 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -135 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17395400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597295 [patent_doc_number] => 20230272090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => IL2RB BINDING MOLECULES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/006528 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18006528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311610 [patent_doc_number] => 12037413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Anti-NME antibody and method of treating cancer or cancer metastasis [patent_app_type] => utility [patent_app_number] => 17/392981 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 157 [patent_no_of_words] => 43963 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 260 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17392981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720488 [patent_doc_number] => 20220213208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => ANTI-BCMA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/444107 [patent_app_country] => US [patent_app_date] => 2021-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17444107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18211898 [patent_doc_number] => 20230058162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => MULTIMERIC CORONAVIRUS BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/386397 [patent_app_country] => US [patent_app_date] => 2021-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198717 [patent_doc_number] => 20210338811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => Combination Therapy of Immunotoxin and Checkpoint Inhibitor [patent_app_type] => utility [patent_app_number] => 17/376319 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18159508 [patent_doc_number] => 20230026100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => ANTI-MUC16 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/375048 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 100033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17375048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198758 [patent_doc_number] => 20210338852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => RI-LABELED HUMANIZED ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/367077 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 359 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367077 [rel_patent_id] =>[rel_patent_doc_number] =>)